Neuroinflammation—persistent inflammation within the nervous system, is increasingly recognized as a central contributor to a range of chronic conditions, including neuropathic pain, neurodegenerative diseases like Parkinson’s and Alzheimer’s, and spinal cord injuries. Unlike acute inflammation, which is a protective response, chronic neuroinflammation disrupts the body’s natural balance, leading to ongoing damage and dysfunction within the nervous system.
Traditional treatments often fail to address the root causes of neuroinflammation. Many current therapies provide only temporary relief and can carry significant side effects, including the risk of addiction associated with opioid-based medications.
EicOsis’s Innovative Approach
At EicOsis, we are pioneering a new class of oral therapeutics that harness the body’s own healing mechanisms to address neuroinflammation and restore balance to the nervous system. Our approach targets the underlying drivers of inflammation and neurodegeneration, offering a promising pathway to improved health and well-being.
Our lead drug candidate, EC5026, is an oral, non-opioid therapy designed to modulate neuroinflammation. By addressing inflammation at its source, EC5026 has the potential to improve outcomes in conditions associated with nervous system dysfunction, including chronic pain and neurodegenerative diseases.
Parkinson’s Disease
Targeting sEH with EicOsis’s lead compound in Parkinson’s Disease represents a multi-modal therapeutic approach, addressing neuroinflammation, oxidative stress, and neurovascular dysfunction—all central to disease progression.
EicOsis is planning on starting an initial clinical trials of its lead compound, EC5026, in patients with Parkinson’s Disease in 2025, with the support of the Michael J. Fox Foundation.
Alzheimer’s Disease
Scientific data suggest that sEH contributes to the neuroinflammatory and neurovascular dysfunction observed in Alzheimer’s Disease, and that inhibiting sEH may represent a promising disease-modifying therapeutic strategy.
Helping patients with Alzheimer’s Disease represents one of the priorities for EicOsis. EicOsis is planning on initiating safety testing in patients with Alzheimer in the next few years. Stay tuned!
